Immunome (IMNM) Equity Average: 2023-2025
Historic Equity Average for Immunome (IMNM) over the last 3 years, with Sep 2025 value amounting to $266.6 million.
- Immunome's Equity Average rose 13.75% to $266.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $266.6 million, marking a year-over-year increase of 13.75%. This contributed to the annual value of $150.5 million for FY2024, which is N/A change from last year.
- Latest data reveals that Immunome reported Equity Average of $266.6 million as of Q3 2025, which was down 7.50% from $288.2 million recorded in Q2 2025.
- In the past 5 years, Immunome's Equity Average ranged from a high of $288.2 million in Q2 2025 and a low of $7.7 million during Q3 2023.
- In the last 3 years, Immunome's Equity Average had a median value of $218.5 million in 2024 and averaged $178.6 million.
- Data for Immunome's Equity Average shows a peak YoY surged of 2,941.03% (in 2024) over the last 5 years.
- Over the past 3 years, Immunome's Equity Average (Quarterly) stood at $63.0 million in 2023, then skyrocketed by 214.45% to $198.0 million in 2024, then increased by 13.75% to $266.6 million in 2025.
- Its Equity Average stands at $266.6 million for Q3 2025, versus $288.2 million for Q2 2025 and $244.1 million for Q1 2025.